Home » Newsletters » BioWorld

BioWorld

Nov. 23, 2010

View Archived Issues

Second hESC Trial Clears FDA; ACT Set to Start Phase I/II Study

Stock Movers

Clinic Roundup

Financings Roundup

Other News To Note

Regeneron Stock Up 19.7% After Positive VEGF Trap-Eye Report

The talk from Regeneron Pharmaceuticals Inc. is of trials – clinical and, perhaps, legal. (BioWorld Today) Read More

BI Hails F-Star's Fcab Platform in Seven-Target Antibody Deal